ResultsCX Earns Great Place To Work® Certification™ in Seven Countries, Including First Time Recognition in India and the UK
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- ResultsCX, a provider of Customer Experience Management (CXM) services to leading global companies including Fortune 100 and FTSE 250 firms, today announced it was certified in seven countries by Great Place To Work®, the global authority on workplace culture, employee experience, and leadership. This year's award marks the fourth consecutive year ResultsCX's United States location has earned Great Place To Work® Certification ™, with the company's operations in Honduras, Mexico, Philippines and Bulgaria receiving this distinction for multiple years, and its India and UK operations achieving certification for the first time.
'The past two years have been a period of rapid expansion for ResultsCX. What truly sets this growth apart is our ability to integrate not just at the technological and operational levels, but at a much deeper cultural level,' said ResultsCX Chief Executive Officer Rajesh Subramanian. 'Since 2022, we have completed three strategic acquisitions and launched new customer operations in India. Throughout this journey, our teams have continued to foster an inclusive culture while prioritizing employee wellbeing across a diverse and evolving workforce. The consecutive certifications by Great Place To Work® are a testament to this commitment.'
As a purpose-driven employer, ResultsCX is committed to creating positive workplace environments across its global operations, ensuring that all employees feel included and seen. The company has consistently demonstrated its commitment to an inclusive and engaging culture through initiatives focused on gender equity, professional development, and environmental, social, and governance (ESG) impact. These efforts are reflected in the latest Great Place To Work® survey, where the company received positive feedback.
'Our focus is squarely on the wellbeing of our employees," said ResultsCX Chief Human Resources Officer Mark Cunningham. 'By creating the right environment and fostering a supportive culture, we achieve exceptional results for our employees and our customers. This recognition reflects the collective commitment of our entire team to making this a truly exceptional place to work.'
According to Great Place To Work® research, job seekers are 4.5 times more likely to find a great manager at a Certified great workplace. Additionally, employees at Certified workplaces are 93% more likely to look forward to coming to work, and are twice as likely to be paid fairly, earn a fair share of the company's profits, and have a fair chance at promotion.
'Great Place To Work® Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience,' says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work®. 'By successfully earning this recognition, it is evident that ResultsCX stands out as one of the top companies in the world to work for, providing a great workplace environment for its employees.'
About Great Place To Work ® Certification™
Great Place To Work® Certification™ is the most definitive 'employer-of-choice' recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work® Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work® Certified.
About Great Place To Work ®
As the global authority on workplace culture, Great Place To Work® brings 30 years of groundbreaking research and data to help every place become a Great Place To Work® for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work® Certified™ or receiving recognition on a coveted Best Workplaces™ List. Learn more at greatplacetowork.com.
About ResultsCX
ResultsCX is a leading provider of transformational Customer Experience Management (CXM) solutions to 130+ global brands, including Fortune 100 and FTSE 250 companies. For 30+ years, we have been driving superior customer and business outcomes for brands across Healthcare, Media, Telecom, Fast Growth technology, Retail, Banking and Financial Services, and other industries globally.
Our award-winning approach helps brands prioritize investments and build digitally influenced customer journeys, creating high-value impact across three areas: Revenue Acceleration, Cost Optimization, and Enhanced Experience. Supported by 24,000+ colleagues and 23 engagement hubs worldwide, our innovative solutions and services solve persistent customer experience challenges, making life easier for millions of consumers. For more information about ResultsCX and its award-winning customer experience solutions, please visit www.resultscx.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
44 minutes ago
- Business Wire
VeriSilicon Expands DSP Portfolio with Silicon-Proven ZSP5000 Vision Core Series for Edge Intelligence
SHANGHAI--(BUSINESS WIRE)--VeriSilicon ( today released the ZSP5000 Digital Signal Processing (DSP) series IPs, which are based on its fifth-generation silicon-proven DSP architecture. This product line adopts a highly scalable and energy-efficient design, and has been deeply optimized for compute-intensive workloads such as computer vision and embedded AI. Combined with the configurable nature of the architecture, this series of IP can provide excellent solutions with both energy and computing efficiency for various edge devices. With the growing adoption of OpenCV and the increasing demand for computer vision workloads alongside NPUs in edge intelligence computing, we are introducing the ZSP5000—our next-generation DSP IP series. Share The ZSP5000 series IPs include ZSP5000, ZSP5000UL, ZSP5000L, and ZSP5000H, delivering scalable vector processing performance ranging from 32 to 256 8-bit Multiply-Accumulate (MAC) operations per cycle. For even higher performance, VeriSilicon's multi-core ZSP5400H can combine multiple ZSP5000H cores in a multi-cluster architecture to further scale computing capability. The ZSP5000 series features a rich and intuitive instruction set optimized for ease of programming and efficient performance tuning, while its dedicated instructions accelerate common imaging and signal processing tasks such as vector-scalar arithmetic, horizontal reductions, permutations, shifts, table lookups, clamping, and averaging. It integrates the ZTurbo coprocessor interface, allowing customers to easily add custom instructions and hardware accelerators within the same pipeline, and is compatible with the OpenCV Application Programming Interface (API), ensuring seamless integration with the mainstream computer vision frameworks. Additionally, the ZSP5000 series is equipped with a full-featured memory subsystem, a multi-channel 3D DMA engine, and a scalable multicore configuration, supporting flexible deployment for a broad spectrum of applications. The ZSP5000 series IPs are backward compatible with VeriSilicon's scalar ZSPNano series, efficiently handling mixed MCU and DSP workloads. VeriSilicon also offers comprehensive ZView development tools, including an Eclipse-based Integrated Development Environment (IDE), cycle-accurate simulator, optimizing compiler, debugger, and profiling tools, streamlining software development and system integration. 'With the growing adoption of OpenCV and the increasing demand for computer vision workloads alongside NPUs in edge intelligence computing, we are introducing the ZSP5000—our next-generation DSP IP series. It supports the industry-standard OpenCV API, enables streamlined interfacing with NPUs via our FLEXA interface, and integrates built-in audio processing capabilities for multi-modal applications,' said Weijin Dai, Chief Strategy Officer, Executive Vice President, and General Manager of the IP Division at VeriSilicon. 'Energy efficiency is key at the edge, and the ZSP5000 series IPs feature an optimized memory access architecture to minimize processor power consumption. It also features ZTurbo, a custom instruction extension mechanism designed for targeted applications, which enables further power and performance optimization through seamless integration of hardware accelerators. Our leading customers are already leveraging these capabilities to achieve significant advancements in power and performance.' VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit:
Business Wire
44 minutes ago
- Business Wire
AGC Biologics Expands Cell Therapy Development Operations to Asia to Serve Growing Market Need
TOKYO--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.'s Yokohama Technical Center, marking the latest step in the global expansion of the company's Global Cell and Gene Technologies Division. The improved geographical footprint allows AGC Biologics to better serve customers requiring autologous and allogeneic products across all markets, with cell therapy manufacturing now available in three continents (Milan, Italy – Longmont, Colorado, U.S. – Yokohama, Japan). This new site precedes the opening of a new AGC Biologics Yokohama manufacturing facility on schedule to be operational in 2027 with pre-clinical through commercial services for mammalian-based protein biologics, cell therapies, and messenger RNA. The Yokohama location will provide process transfer and manufacturing services for pre-clinical and clinical trials to serve an expanding global cell therapy market. Its core technologies include induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, and CAR-T cell therapies. AGC Biologics Cell and Gene Technology Center of Excellence in Milan, with its nine product approvals by the EMA and FDA, hundreds of batches manufactured, and 30-year track record, will support and enable the successful ramp up of operation in the new Yokohama site. 'In a cell and gene therapy market of high volatility and witnessing consolidation of CDMOs, AGC Biologics is among the few experiencing significant growth and success. We are now building on this success to complete the vision of having a truly global offering,' said Luca Alberici, Executive Vice President of Global Cell and Gene Technologies at AGC Biologics. 'Now Asian developers can benefit from having a local supply within one of the best global infrastructures on the market for cell therapy. Moreover, customers can continue to leverage the offering of viral vector central supply in our Milan facility, which supplies around a third of the ex vivo gene therapy product approved for commercialization. AGC Biologics, through its proprietary ProntoLVV and BravoAAV platforms, aims to offer viral vectors at a sustainable cost for its clients targeting less than 1,000€ per CAR-T patient.' 'Our team of friendly experts in Milan have a strong reputation for collaboration and working side-by-side with customers to achieve clinical, late-phase, and commercial successes,' said Jun Takami, Senior Vice President and General Manager, Japan Region and Yokohama Facility. 'As part of this next major phase for cell therapy in the region, our Yokohama team is ready to support partners in accelerating drug development timelines while maintaining the highest quality standards in the industry." AGC Biologics is a part of AGC Inc.'s Life Science Company. The Life Science company operates over 10 facilities worldwide focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. The AGC Inc. Yokohama Technical Center, built in 2020, is dedicated to advancing AGC Inc.'s research and development capabilities in materials science, chemical processes, and biotechnology. Please visit to learn more about AGC Biologics' global network of services for protein biologics and cell and gene therapies. About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide.
Business Wire
2 hours ago
- Business Wire
Delek Logistics Partners, LP Announces Pricing of Upsized Offering of $700 Million of Senior Notes
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Delek Logistics Partners, LP (NYSE: DKL) ('Delek Logistics') announced today that it, along with Delek Logistics Finance Corp., a subsidiary of Delek Logistics, priced an upsized offering of $700 million in aggregate principal amount of 7.375% senior notes due 2033 (the 'Notes') at par. The offering is expected to close June 30, 2025, subject to satisfaction of customary closing conditions. Delek Logistics intends to use the net proceeds from the offering to repay a portion of the outstanding borrowings under its revolving credit facility. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in an offering exempt from registration in reliance on Rule 144A under the Securities Act of 1933, as amended (the 'Securities Act'), and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act. The Notes and related guarantees have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States without registration or an applicable exemption from the registration requirements of the Securities Act or any applicable state securities laws. This press release is being issued pursuant to Rule 135c under the Securities Act, and is neither an offer to sell nor a solicitation of an offer to buy the Notes or any other securities and shall not constitute an offer to sell or a solicitation of an offer to buy, or a sale of, the Notes or any other securities in any jurisdiction in which such offer, solicitation or sale is unlawful. About Delek Logistics Partners, LP Delek Logistics is a midstream energy master limited partnership headquartered in Brentwood, Tennessee. Through its owned assets and joint ventures located primarily in and around the Permian Basin, the Delaware Basin and other select areas in the Gulf Coast region, Delek Logistics provides gathering, pipeline and other transportation services primarily for crude oil and natural gas customers, storage, wholesale marketing and terminalling services primarily for intermediate and refined product customers, and water disposal and recycling services. Delek US Holdings, Inc. (NYSE: DK) owns the general partner interest as well as a majority limited partner interest in Delek Logistics, and is also a significant customer. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the closing of the offering and the anticipated use of the net proceeds therefrom. These statements may contain words such as 'possible,' 'believe,' 'should,' 'could,' 'would,' 'predict,' 'plan,' 'estimate,' 'intend,' 'may,' 'anticipate,' 'will,' 'if,' 'expect' or similar expressions, as well as statements in the future tense, are made as of the date they were first issued and are based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Delek Logistics' control. Delek Logistics' actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including, but not limited to, market risks and uncertainties, including those which might affect the offering. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed in Delek Logistics' filings and reports with the U.S. Securities and Exchange Commission ('SEC'), including the Annual Report on Form 10-K for the year ended December 31, 2024, the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 and other reports and filings with the SEC.
